Phase I Trial of Escalating Doses of Paclitaxel Plus Doxorubicin and Dexrazoxane in Patients With Advanced Breast Cancer
- 1 March 1999
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (3), 880
- https://doi.org/10.1200/jco.1999.17.3.880
Abstract
PURPOSE: To determine the maximum-tolerable dose (MTD) of paclitaxel given as a 3-hour intravenous (IV) infusion that could be used in conjunction with doxorubicin and dexrazoxane, and to determine...Keywords
This publication has 24 references indexed in Scilit:
- AbstractsBreast Cancer Research and Treatment, 1997
- Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.Journal of Clinical Oncology, 1997
- Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.Journal of Clinical Oncology, 1997
- Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.Journal of Clinical Oncology, 1997
- Paclitaxel induces significant changes in epidoxorubicin distribution in miceAnnals of Oncology, 1996
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995
- Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimensBritish Journal of Cancer, 1993
- Pharmacokinetics of the Cardioprotector ADR-529 (ICRF-187) in Escalating Doses Combined With Fixed-Dose DoxorubicinJNCI Journal of the National Cancer Institute, 1992
- ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.Journal of Clinical Oncology, 1992
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979